Eris Lifesciences Intrinsic Value
Eris Lifesciences (ERIS) median intrinsic value is ₹2801.20 from 9 valuation models (range ₹527–₹3502), vs current price ₹1400.60 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Read ERIS dividend payout details for the complete payout history and dividend yield track record.
ERIS Valuation Methods Summary — DCF, Graham Number & P/E
Eris Lifesciences intrinsic value across 9 models vs current price ₹1400.60 — upside/downside and value range per method. Analyse Eris Lifesciences shareholding analysis to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1812.80 | ₹1450.24 - ₹2175.36 | +29.4% | EPS: ₹82.40, Sector P/E: 22x |
| Book Value Method | asset | ₹3501.50 | ₹3151.35 - ₹3851.65 | +150.0% | Book Value/Share: ₹2787.86, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2801.20 | ₹2521.08 - ₹3081.32 | +100.0% | Revenue/Share: ₹2157.14, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2801.20 | ₹2521.08 - ₹3081.32 | +100.0% | EBITDA: ₹1080.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3501.50 | ₹2801.20 - ₹4201.80 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹527.36 | ₹474.62 - ₹580.10 | -62.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1273.08 | ₹1145.77 - ₹1400.39 | -9.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2801.20 | ₹2521.08 - ₹3081.32 | +100.0% | ROE: 28.6%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹2273.47 | ₹2046.12 - ₹2500.82 | +62.3% | EPS: ₹82.40, BVPS: ₹2787.86 |
ERIS Intrinsic Value vs Market Price — All Valuation Models
Eris Lifesciences fair value range ₹527–₹3502 vs current market price ₹1400.60 across 9 valuation models. For current market price and key ratios, visit Eris Lifesciences share price today.
ERIS Intrinsic Value Analysis — Undervalued or Overvalued?
Eris Lifesciences median intrinsic value ₹2801.20, current price ₹1400.60 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of ERIS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Eris Lifesciences (ERIS) is ₹2801.20 (median value). With the current market price of ₹1400.60, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹527.36 to ₹3501.50, indicating ₹527.36 - ₹3501.50.
Is ERIS undervalued or overvalued?
Based on our multi-method analysis, Eris Lifesciences (ERIS) appears to be trading below calculated value by approximately 100.0%.
ERIS Financial Health — Key Ratios vs Industry Benchmarks
Eris Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.11 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 28.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 36.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.41x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
ERIS Cash Flow Quality — Operating & Free Cash Flow
Eris Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,065 Cr | ₹1,026 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹486 Cr | ₹-428 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹292 Cr | ₹-196 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹378 Cr | ₹218 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹375 Cr | ₹214 Cr | Positive Free Cash Flow | 8/10 |